Literature DB >> 16196492

Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes.

Sébastien A Gittens1, Geeti Bansal, Cezary Kucharski, Mark Borden, Hasan Uludag.   

Abstract

Protein conjugation to bisphosphonic acids (BPs), such as 1-amino-1,1-diphosphonate methane (aminoBP) and 3,5-di(ethylamino-2,2-bisphosphono)benzoic acid (diBP), was proposed as a foundation for bone-specific delivery of protein therapeutics. This study was performed to directly compare the mineral affinity of protein-BP conjugates prepared by three different approaches. Fetuin, serving as a model protein, was derivatized with BPs by the following approaches: (i) by attaching the aminoBPs onto protein lysines using succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC); (ii) by attaching the aminoBPs onto protein carbohydrates using 4-(maleimidomethyl)-cyclohexane-1-carboxyl-hydrazide (MMCCH), and (iii) by conjugating diBP to protein lysines using the carbodiimide chemistry. The results indicated that conjugation of aminoBP and diBP to fetuin by all three means unequivocally enhanced the protein's affinity for hydroxyapatite in vitro. Similarly, conjugation of aminoBP and diBP onto fetuin increased the protein's retention in a mineral-containing matrix (Pro-Osteon) when the proteins were implanted in a rat subcutaneous model. Upon parenteral administration, however, no discernible differences were found between the SMCC- or MMCCH-linked conjugates and unmodified fetuin to target to bony tissues. DiBP-fetuin conjugates, however, led to successful bone targeting after intravenous injection in rats. We conclude that all three conjugation schemes were equally effective in imparting an affinity to the proteins toward mineral-containing matrices. Bone targeting, however, was achieved only with diBP conjugation to fetuin, supportive of the superior ability of this BP with a higher density of bisphosphonic acid groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16196492     DOI: 10.1021/mp050017u

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  4 in total

1.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

2.  Characterization of synthesized NANO-encapsulated drug for bone loss on hind limb suspension rat model by NMR and micro-CT.

Authors:  Qingwen Ni; Hong Dixon; Gloria Gutierrez; Long Bi; Yi-Xian Qin
Journal:  Adv Biosci Bioeng (N Y)       Date:  2014-06-14

3.  Multivalent Presentation of Peptide Targeting Groups Alters Polymer Biodistribution to Target Tissues.

Authors:  Maureen R Newman; Steven G Russell; Christopher S Schmitt; Ian A Marozas; Tzong-Jen Sheu; J Edward Puzas; Danielle S W Benoit
Journal:  Biomacromolecules       Date:  2017-12-28       Impact factor: 6.988

Review 4.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.